David S. Goldstein

LBA80 Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study

Phenoconversion in pure autonomic failure: a multicentre prospective longitudinal cohort study

INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer

Sinus Tachycardia: a Multidisciplinary Expert Focused Review

Research Opportunities in Autonomic Neural Mechanisms of Cardiopulmonary Regulation

Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture

Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1

A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment

Postural orthostatic tachycardia syndrome (POTS): Priorities for POTS care and research from a 2019 National Institutes of Health Expert Consensus Meeting – Part 2

Enhanced tyrosine hydroxylase activity induces oxidative stress, causes accumulation of autotoxic catecholamine metabolites, and augments amphetamine effects in vivo

Different phenoconversion pathways in pure autonomic failure with versus without Lewy bodies

Elevated COUP-TFII expression in dopaminergic neurons accelerates the progression of Parkinson’s disease through mitochondrial dysfunction

Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies

Natural history of pure autonomic failure: A <scp>U</scp>nited <scp>S</scp>tates prospective cohort

Pleiotropic neuropathological and biochemical alterations associated with Myo5a mutation in a rat Model

Determinants of denervation-independent depletion of putamen dopamine in Parkinson's disease and multiple system atrophy

Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study

Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration

Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy

Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo

Determinants of buildup of the toxic dopamine metabolite<scp>DOPAL</scp>in Parkinson's disease

Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus

Phosphorylated α-Synuclein in Parkinson’s Disease

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure